ArticleOncoTargets and therapy2020
Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Shared molecular mechanisms of common differentially expressed genes (C-DEGs) linking gallbladder stones to carcinogenesis: integrated bioinformatics and experimental validation.Cancer cell international · 2026Article
- Evolutionary Transcriptomics of Cancer Development.International journal of molecular sciences · 2025Article
- VCAN in the extracellular matrix drives glioma recurrence by enhancing cell proliferation and migration.Frontiers in neuroscience · 2024Article
- Upregulation of CELSR1 expression promotes ovarian cancer cell proliferation, migration, and invasion.Medical oncology (Northwood, London, England) · 2023Article
- MiRNA-30a-5p/VCAN Arrests Tumor Metastasis via Modulating the Adhesion of Lung Adenocarcinoma Cells.Applied biochemistry and biotechnology · 2023Article
- Transcriptome sequencing identifies prognostic genes involved in gastric adenocarcinoma.Molecular and cellular biochemistry · 2023Article
- Identification of survival-associated biomarkers based on three datasets by bioinformatics analysis in gastric cancer.World journal of clinical cases · 2023Article
- Cortactin contributes to the tumorigenesis of gastric cancer by activating ERK/MMP pathway.Heliyon · 2023Article
- Pan-cancer analysis of the oncogenic role of the core osteosarcoma gene VCAN in human tumors.American journal of translational research · 2023Article
- Article
- Proteomic profiling identifies novel diagnostic biomarkers and molecular subtypes for mucinous tubular and spindle cell carcinoma of the kidney.The Journal of pathology · 2022Article
- Identification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning.Frontiers in endocrinology · 2022Article
- An integrated analysis of prognostic mRNA signature in early- and progressive-stage gastric adenocarcinoma.Frontiers in molecular biosciences · 2022Article
- Significance of monocyte infiltration in patients with gastric cancer: A combined study based on single cell sequencing and TCGA.Frontiers in oncology · 2022Article
- Integrated bioinformatics analysis of differentially expressed genes and immune cell infiltration characteristics in Esophageal Squamous cell carcinoma.Scientific reports · 2021Article
- INHBA promotes the proliferation, migration and invasion of colon cancer cells through the upregulation of VCAN.The Journal of international medical research · 2021Article
- Review
- Novel CircRNAs in Hub ceRNA Axis Regulate Gastric Cancer Prognosis and Microenvironment.Frontiers in medicine · 2021Article
- Circular RNA Circ-0002570 Accelerates Cancer Progression by Regulating VCANFrontiers in oncology · 2021Article
Corrections and comments
- Erratum issuedErratum:2020
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsAccording to 5 GC tissues and corresponding general tissues, mRNA expression profiles were taken here. VCAN expression in tissues was confirmed by quantitative reverse transcription polymerase reaction (qRT-PCR). The effect generated by VCAN expression on cell proliferating, invading and migrating processes was assessed in vitro with knockdown and overexpression strategies. Moreover, the relationships between immune response and VCAN expression in GC were assessed with the use of the software online.
resultsThere are 181 genes up-regulated and 530 genes down-regulated in GC. According to pathway study, the mentioned differently expressed mRNAs showed correlations with a number of vital physiological processes, cellular components, molecular functions and critical cancer signal pathways. VCAN was reported to be noticeably promoted in GC tissues and related to individual cancer age, race, and stages. VCAN was up-regulated in 16 GC tissues compared to adjacent non-tumorous tissue specimens via qRT-PCR. GC patients exhibiting higher VCAN expression had less post-progression survival (PPS), first progression (FP) and overall survival (OS). Experimental processes in vitro revealed VCAN knockdown hindered, proliferated, invaded, and migrated levels of GC cells, whereas overexpression of VCAN played the opposite effect. Immune factors may interact with VCAN mRNA in GC, and VCAN was found noticeably linked with regulatory T cells (Tregs).
conclusionAccording to the mentioned results, VCAN critically impacts GC progression. Accordingly, VCAN is likely to be a potentially feasible prognosis marking element and a prominent cancer drug for GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.